Navigation Links
Lilly and Incyte's Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis
Date:6/8/2012

BERLIN, June 8, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (Nasdaq: INCY) announced the presentation of 12-week results from a Phase IIb study of baricitinib, formerly LY3009104 (INCB28050), an orally available janus kinase (JAK) inhibitor, in patients with active rheumatoid arthritis (RA). The results were presented as a late-breaking oral presentation at the European League Against Rheumatism's (EULAR) Annual European Congress of Rheumatology [EULAR abstract LB0005: 12-Week Results of a Phase IIb Dose-Ranging Study of LY3009104 (INCB028050), an Oral JAK1/JAK2 Inhibitor, in Combination with Traditional DMARDs in Patients with Rheumatoid Arthritis].

The Phase IIb randomized double-blind, placebo-controlled, dose-ranging study, known as JADA, involved a total of 301 patients with active RA on stable doses of methotrexate. Patients were randomized to receive either placebo or one of four once-daily doses of baricitinib (1 mg, 2 mg, 4 mg or 8 mg) for 12 weeks.

Primary Endpoint Achieved

The Phase IIb trial achieved the primary endpoint by demonstrating a statistically significant difference in the American College of Rheumatology 20 (ACR20) response between the combined 4 mg and 8 mg baricitinib groups (76 percent) compared with placebo (41 percent) after 12 weeks of treatment (p<0.001). Statistically significant improvement was observed at the first assessment point after two weeks of treatment and was sustained through week 12.

Summary of Secondary Endpoints

A statistically significant difference in response for the ACR20, ACR50 and ACR70 secondary endpoints was observed with the 1 mg, 4 mg and 8 mg dose groups compared with placebo.

ACR20

  • 8 mg: 78 percent (p<0.001)
  • 4 mg: 75 percent (p<0.001)
  • 2 mg: 54 percent (
    '/>"/>

SOURCE Eli Lilly and Company; Incyte Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
2. Lilly Oncology To Disclose New Pipeline Data At ASCO 2012
3. Lilly Applauds Law Enforcement Officials for their Successful Investigation and Recovery of Pharmaceuticals Stolen from Connecticut Distribution Center
4. Lilly Sets Date for Lilly Diabetes Pipeline Update to the Investment Community
5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
6. DiversityInc Names Lilly a Top Company for Diversity
7. Study Showed Patients Treated With The miraDry© System Experienced 82 Percent Sweat Reduction On Average
8. InspireMD Announces Positive 3-Year Results from Extended MAGICAL trial
9. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
10. Boston Scientific Announces Positive Data From Lotus™ Transcatheter Aortic Valve Trial
11. Life Extension Foundation® study finds Cognitex® with NeuroProtection Complex may provide a positive impact on cognitive performance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... and HAMPTON, N.J. , March 5, ... MNK ), a leading global specialty biopharmaceutical company, ... today that they have entered into a definitive agreement ... Inc. from a Madison Dearborn -led investor group ... Subject to customary closing conditions, the parties ...
(Date:3/5/2015)... 05, 2015 Research and Markets ( ... "Global Rising Stars Outlook 2015" report to their ... are being sought after with fresh vigor as new ... which is poised to bring a paradigm change in ... is the Stem cell therapy/Regenerative Medicine space. ...
(Date:3/5/2015)... -- According to a new market research ... Disposables), by Type (Invasive, Minimally Invasive, Non-Invasive), by End-User ... - Analysis & Global Forecast to 2019" , the ... $1,107.4 Million by 2019 from $887.8 Million in 2014, ... 4.5% during the forecast period. Browse ...
Breaking Medicine Technology:Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 2Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 3Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 4Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 5Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 6Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 7Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 8Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 9Global Pharma Rising Stars Outlook 2015 2Hemodynamic Monitoring Systems Market Worth $1,107.4 Million by 2019 2Hemodynamic Monitoring Systems Market Worth $1,107.4 Million by 2019 3Hemodynamic Monitoring Systems Market Worth $1,107.4 Million by 2019 4
... ... ... ... are keyed by longUrl, so we need to grab the first one. for (var r in data.results) { first_result ...
... STEWARTVILLE, Minn., Oct. 25 Rochester Medical Corporation (Nasdaq: ... close on Thursday, November 4, 2010.  The Company will then ...  The call will begin at 3:30 p.m. central time (4:30 ... by Thomson/CCBN and can be accessed at Rochester Medical,s website ...
Cached Medicine Technology:Sanofi-aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple Sclerosis 2Sanofi-aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple Sclerosis 3Sanofi-aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple Sclerosis 4Sanofi-aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple Sclerosis 5Sanofi-aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple Sclerosis 6Sanofi-aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple Sclerosis 7Sanofi-aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple Sclerosis 8Sanofi-aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple Sclerosis 9Sanofi-aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple Sclerosis 10Sanofi-aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple Sclerosis 11Rochester Medical Announces Fourth Quarter 2010 Earnings Conference Call Thursday, November 4, 2010 2
(Date:3/5/2015)... 2015 Shania Twain will be touring ... decade. She has hinted that this will be her final ... perform one last time. She has had a residency in ... sweetheart has millions of loyal fans around the world. After ... Canada, and on June 30th she will be at Madison Square ...
(Date:3/5/2015)... York, New York (PRWEB) March 05, 2015 ... of men who allegedly suffered heart attacks, strokes and ... prescription low testosterone therapies continue to move forward in ... Court, Northern District of Illinois. According to a Case ... set forth procedures for the use of master pleadings ...
(Date:3/5/2015)... Los Angeles, CA (PRWEB) March 05, 2015 ... online article titled “Butt Augmentation, Labiaplasty on the Rise, ... surveys reported by the American Society for Aesthetic ... Plastic Surgeons . Both groups reported a year-over-year doubling ... one of the physicians quoted in the article, this ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 ... in healthcare communications and education, announced today its ... (AMP), the nation’s only medical conference designed for ... ischemia and lower limb amputation due to vascular ... family of innovative, evidence-based publications and CME activities ...
(Date:3/5/2015)... Venice, FL (PRWEB) March 05, 2015 ... their 15th annual listing of “Pros to Know” in ... announce that two members of MEBC’s leadership team were ... Rhodes were nominated and received this award due to ... use of innovative methods for meeting and resolving client ...
Breaking Medicine News(10 mins):Health News:Shania Twain Tickets: Ticket Down Announces Shania Twain's 2015 “Rock This Country” North American Tour 2Health News:Shania Twain Tickets: Ticket Down Announces Shania Twain's 2015 “Rock This Country” North American Tour 3Health News:Testosterone Lawsuits Move Forward, as Bernstein Liebhard LLP Comments on Most Recent Order Issued in Federal Litigation 2Health News:Testosterone Lawsuits Move Forward, as Bernstein Liebhard LLP Comments on Most Recent Order Issued in Federal Litigation 3Health News:Testosterone Lawsuits Move Forward, as Bernstein Liebhard LLP Comments on Most Recent Order Issued in Federal Litigation 4Health News:The Kim Kardashian and Jennifer Lopez Effect: Butt Augmentations Double from 2013 to 2014 2Health News:HMP Holdings Acquires The Amputation Prevention Symposium (AMP) 2Health News:HMP Holdings Acquires The Amputation Prevention Symposium (AMP) 3Health News:MEBC Leaders Awarded Supply Demand Chain Executive Pros to Know Title For 2015 2
... Glenn Hackbarth (MedPAC) and Bruce Bradley (General,Motors) - ... 1 The ABIM Foundation,will dedicate its efforts ... concepts,of medical professionalism and accountability in health care ... In addition, the Foundation announced that officers of ...
... Care Advantage, JACKSONVILLE, Fla., July 1 ... home,health care agency with 11 years experience in ... in revenue. Home Care Advantage is the largest ... the largest,rehabilitation provider in Jacksonville, with its 143-bed ...
... -- The first batch of imported food,( ... for the Olympic Games has arrived. The 24.269 ... in Shanghai on June 18. To ensure the,smooth ... Quarantine Bureau,took great care in their preparations prior ...
... 20% of persons aged over 55 use colonoscopies for ... insurance funds have covered the costs since 2002. This ... Database published in the current edition of Deutsches ... , http://www.aerzteblatt.de/v4/archiv/pdf.asp?id=60551 , The authors evaluated ...
... What began as a college course project to design ... their kind, designed as therapy for children with cerebral ... affects the development of the brain and the motor ... occupational therapy have been shown to be effective treatments ...
... junk food had higher cholesterol, blood fats into adulthood, ... -- Eating an unhealthy diet during pregnancy may raise ... and blood sugar levels, British researchers report. , In ... one group of females a diet of processed junk ...
Cached Medicine News:Health News:ABIM Foundation Announces New Focus and Governance 2Health News:ABIM Foundation Announces New Focus and Governance 3Health News:Jacksonville's Largest Rehab Provider Acquires Largest Home Health Agency 2Health News:China Improves Safety Management on Imported Foods in Preparation for Olympic Games 2Health News:Toys and technology for rehabilitation in cerebral palsy patients 2Health News:Toys and technology for rehabilitation in cerebral palsy patients 3Health News:Mom's Unhealthy Diet May Have Long-Term Impact on Baby 2
... The Bledsoe Revolution Knee ... speed fitting under post-op ... the surgeon or authorized ... post-op fitting and application ...
The Bledsoe Post-Op Knee Brace is designed to provide maximum protection without sacrificing comfort and quick, easy application....
... Room Knee Brace frees the ... the time-consuming post-op fitting and ... more complex brace designs. The ... provides the same benefits as ...
... Cronin, Inc. is a ... Footwear, Orthopedic Softgoods, and ... Our products are of ... available in the USA ...
Medicine Products: